These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27076148)

  • 1. Anti-Lyme Subunit Vaccines: Design and Development of Peptide-Based Vaccine Candidates.
    Small CM; Mwangi W; Esteve-Gassent MD
    Methods Mol Biol; 2016; 1403():471-86. PubMed ID: 27076148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delineating Surface Epitopes of Lyme Disease Pathogen Targeted by Highly Protective Antibodies of New Zealand White Rabbits.
    Rogovskyy AS; Caoili SEC; Ionov Y; Piontkivska H; Skums P; Tsyvina V; Zelikovsky A; Waghela SD
    Infect Immun; 2019 Aug; 87(8):. PubMed ID: 31085705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
    Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
    J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoinformatics and Reverse Vaccinology Driven Predication of a Multi-epitope Vaccine against
    Hussain Z; Hayat C; Shahab M; Sikandar R; Bibi H; Kamil A; Zheng G; Liang C
    Curr Pharm Des; 2023; 29(19):1504-1515. PubMed ID: 37073655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and development of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U
    PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel approach of virulome based reverse vaccinology for exploring and validating peptide-based vaccine candidates against the most troublesome nosocomial pathogen: Acinetobacter baumannii.
    Ahmad S; Azam SS
    J Mol Graph Model; 2018 Aug; 83():1-11. PubMed ID: 29753164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational antigenic epitope prediction by calculating electrostatic desolvation penalties of protein surfaces.
    Fiorucci S; Zacharias M
    Methods Mol Biol; 2014; 1184():365-74. PubMed ID: 25048135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial-infection protocols allow immunodetection of novel Borrelia burgdorferi antigens suitable as vaccine candidates against Lyme disease.
    Wallich R; Jahraus O; Stehle T; Tran TT; Brenner C; Hofmann H; Gern L; Simon MM
    Eur J Immunol; 2003 Mar; 33(3):708-19. PubMed ID: 12616491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lyme borreliosis vaccination: the facts, the challenge, the future.
    Schuijt TJ; Hovius JW; van der Poll T; van Dam AP; Fikrig E
    Trends Parasitol; 2011 Jan; 27(1):40-7. PubMed ID: 20594913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines.
    Nassal M; Skamel C; Vogel M; Kratz PA; Stehle T; Wallich R; Simon MM
    Int J Med Microbiol; 2008 Jan; 298(1-2):135-42. PubMed ID: 17888729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice.
    Bockenstedt LK; Fikrig E; Barthold SW; Flavell RA; Kantor FS
    J Immunol; 1996 Dec; 157(12):5496-502. PubMed ID: 8955199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
    O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
    Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural vaccinology considerations for in silico designing of a multi-epitope vaccine.
    Negahdaripour M; Nezafat N; Eslami M; Ghoshoon MB; Shoolian E; Najafipour S; Morowvat MH; Dehshahri A; Erfani N; Ghasemi Y
    Infect Genet Evol; 2018 Mar; 58():96-109. PubMed ID: 29253673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combating tigecycline resistant Acinetobacter baumannii: A leap forward towards multi-epitope based vaccine discovery.
    Ahmad S; Ranaghan KE; Azam SS
    Eur J Pharm Sci; 2019 Apr; 132():1-17. PubMed ID: 30797936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.
    Lovrich SD; Jobe DA; Schell RF; Callister SM
    Clin Diagn Lab Immunol; 2005 Jun; 12(6):746-51. PubMed ID: 15939749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
    Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
    Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of lyme disease: promising research or sisyphean task?
    Krupka M; Zachova K; Weigl E; Raska M
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):261-75. PubMed ID: 21633917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
    Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
    Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.